TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Core Insights - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment [3] Group 1: Company Overview - TScan's lead TCR-T therapy candidates are aimed at treating patients with hematologic malignancies to prevent relapse after allogeneic hematopoietic cell transplantation, specifically through the ALLOHA™ Phase 1 heme trial [3] - The company is expanding its ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets associated with multiple HLA types, to provide customized multiplex TCR-T therapies for various cancers, as seen in the PLEXI-T™ Phase 1 solid tumor trial [3] - TScan is currently enrolling patients in both clinical programs [3] Group 2: Upcoming Events - TScan will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 1:10 p.m. Eastern Time [1] - A webcast of the presentation will be available on the company's website, with an archived replay accessible for 90 days post-event [2]